We spoke with Luca Crippa, CEO and Managing Director at IBSA Farmaceutici, about the company's approach to developing new delivery technologies for existing and natural molecules, its focus on endocrinology, fertility, orthopaedics and aesthetic medicine, and the group's new affiliates in the US, France, Germany and the UK.
... the difference between IBSA and other companies is that we have both pharma and medical devices ... We develop and patent new technologies to deliver either natural molecules like hyaluronic acid or existing chemical entities like progesterone and we take them to the next level.
